Intended for healthcare professionals
Our CompanySubscribeMy AccountLogin
Home/About BMJ/Resources for readers/Publications/Epidemiology for the uninitiated/Chapter 7. Longitudinal studies

Chapter 7. Longitudinal studies

More chapters in Epidemiology for the uninitiated

In a longitudinal study subjects are followed over time with continuous or repeated monitoring of risk factors or health outcomes, or both. Such investigations vary enormously in their size and complexity. At one extreme a large population may be studied over decades. For example, the longitudinal study of the Office of Population Censuses and Surveys prospectively follows a 1% sample of the British population that was initially identified at the 1971 census. Outcomes such as mortality and incidence of cancer have been related to employment status, housing, and other variables measured at successive censuses. At the other extreme, some longitudinal studies follow up relatively small groups for a few days or weeks. Thus, firemen acutely exposed to noxious fumes might be monitored to identify any immediate effects.

Most longitudinal studies examine associations between exposure to known or suspected causes of disease and subsequent morbidity or mortality. In the simplest design a sample or cohort of subjects exposed to a risk factor is identified along with a sample of unexposed controls. The two groups are then followed up prospectively, and the incidence of disease in each is measured. By comparing the incidence rates, attributable and relative risks can be estimated. Allowance can be made for suspected confounding factors either by matching the controls to the exposed subjects so that they have a similar pattern of exposure to the confounder, or by measuring exposure to the confounder in each group and adjusting for any difference in the statistical analysis.

A problem when the cohort method is applied to the study of chronic diseases such as cancer, coronary heart disease, or diabetes is that large numbers of people must be followed up for long periods before sufficient cases accrue to give statistically meaningful results. The difficulty is further increased when, as for example with most carcinogens, there is a long induction period between first exposure to a hazard and the eventual manifestation of disease.

One approach that can help to counter this problem is to carry out the follow up retrospectively. In developing ideas about the fetal origins of coronary heart disease, it was possible to find groups of men and women born in the county of Hertfordshire before 1930 whose fetal and infant growth had been documented. These people were traced, and the cause of death was ascertained for those who had died. Death rates from coronary heart disease could thus be related to weight at birth and at one year old. Obviously, such a study is only feasible when the health outcome of interest can be measured retrospectively. Mortality and cancer incidence can usually be ascertained reliably, but disorders such as asthma may be harder to assess in retrospect. A further requirement is that the selection of exposed people for study should not be influenced by factors related to their subsequent morbidity.

Another modification of the method is to use the recorded disease rates in the national or regional population for control purposes, rather than following up a specially selected control group. This technique is legitimate when exposure to the hazard in the general population is negligible. Thus, in a cohort study of people occupationally exposed to ethylene oxide (used as a sterilant gas and in the manufacture of antifreeze), exposure in the general population was minimal and national death rates could be used as a reference. The numbers of deaths in the cohort were compared with the numbers that would have been expected if subjects had experienced the same death rates specific for age, sex, and calendar period as the general population. 

Clinical follow up studies

What is the prognosis for a 38 year old man who presents with a first epileptic fit, and what advice should he be given about driving? What is the outlook for a manual labourer who has been off work for three months with low back pain? How likely is it that he will be fit to return to his job, and how soon? Questions such as these are investigated by clinical follow up studies – longitudinal studies in which patients with a disease are monitored systematically to establish how their illness progresses and what influences the prognosis.

The need for systematic follow up arises because clinical impressions are often misleading. For example, a neurologist’s view of multiple sclerosis tends to be unduly gloomy. Patients in whom the disease remits without residual disability (a third) do not continue to attend that clinic. Those in whom the disease runs a less favourable course return again and again. A general practitioner might be expected to form a more representative impression, but because the disease is rare he will have only a few patients on his list and will not get a complete picture.

For the findings of a clinical follow up study to be generalised to patients elsewhere, it is important to define precisely how subjects are selected for study. For example, patients presenting with asthma to a respiratory physician are likely to have a different prognosis from those seen in general practice. Interpretation is usually easier if entry to follow up is determined by an event (such as first diagnosis) rather than a state (for example, all patients from a renal unit who are on the waiting list for transplants) as outlook for the latter will often vary according to how long they have been in that state. Most studies also document characteristics of subjects when they enter follow up (such as age, sex, and duration and severity of symptoms) so that the influence of these variables on prognosis can be examined.

The methods of follow up are similar to those used in other longitudinal studies and can be prospective or retrospective. For diseases that are often lethal, the outcome may be expressed as case fatality or survival rates. Case fatality rate (the proportion of episodes of illness that end fatally) describes the short term outcome of a disease, but must be interpreted with caution. An episode of illness does not correspond to a fixed time interval. Often it refers to a period of medical care, as in a coronary care unit, and case fatality rates may therefore be altered merely by varying the length of stay in hospital. To measure outcome over longer periods, survival rates are used. These show the proportion of patients surviving for a specified time from the date of diagnosis or start of treatment. Survival rates may be corrected to allow for deaths from causes other than the disease being studied. By plotting survival rates at different times it is possible to construct survival curves. An example is shown in the figure.

Survival of kidney grafts according to matching for HLA tissue types


International Jobs

Follow us on

  • Twitter
  • Facebook
  • YouTube
  • Pinterest
  • RSS
Cookie settingsCookie PolicyPrivacy policyWebsite T&CsRevenue SourcesHighWire PressSitemap
Copyright © 2020 BMJ Publishing Group Ltd京ICP备15042040号-3